Tier 3 — preclinical
Urolithin A-mediated augmentation of intestinal barrier function through elevated secretory mucin synthesis
Scientific Reports
2024
14(1):15706
Bibliography
- PubMed
- PMID 38977770
- PubMed Central
- PMC11231190
- Funding
- Daicel Corporation partly supported the work.
Study snapshot
| Design | Mouse mechanistic study with Nrf2-deficient and AHR-antagonist experiments plus mucin-producing cell assays |
|---|---|
| Model | Wild-type and Nrf2-deficient mice, DSS colitis model and LS174T mucin-producing cells |
| Sample | Multiple animal and cellular experimental cohorts |
| Intervention | Urolithin A treatment |
| Duration | Varied by experiment |
| Endpoints | MUC2 expression and mucus thickness; Gut permeability; DSS colitis; Nrf2 and AHR signaling; Short-chain-fatty-acid-producing bacteria |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified



